Current and emerging pharmacotherapeutic options for smoking cessation

Area of Science:

• Public Health
• Pharmacology
• Addiction Medicine

Background:

• Tobacco smoking is a leading preventable cause of death globally, with increasing prevalence in developing nations.
• Nicotine dependence is a chronic condition often necessitating multiple quit attempts, highlighting the need for effective cessation aids.
• Established first-line pharmacotherapies exist but their use in marginalized populations (indigenous, mentally ill, youth, pregnant/breastfeeding) is less understood.

Purpose of the Study:

• To review existing and developing pharmacotherapeutic options for smoking cessation.
• To identify gaps in current clinical practice regarding smoking cessation treatments.
• To provide recommendations for future research and clinical evaluations of cessation strategies.

Main Methods:

• Systematic literature review of pharmacotherapeutic and other smoking cessation interventions.
• Analysis of efficacy and safety data for first-line and alternative cessation medications.
• Identification of research gaps, particularly concerning marginalized populations.

Main Results:

• First-line pharmacotherapies like varenicline tartrate, bupropion hydrochloride, and nicotine replacement therapy (NRT) are effective in the general population.
• Limited data exists on the efficacy and safety of these treatments in diverse and marginalized groups.
• Despite available treatments, relapse remains common, indicating a need for novel approaches.

Conclusions:

• Further research is crucial to optimize smoking cessation strategies for all populations, especially vulnerable groups.
• Development of alternative pharmacotherapies and comprehensive cessation programs is needed to address ongoing relapse.
• Addressing gaps in clinical practice will enhance the effectiveness of tobacco dependence treatment.